Compare FSBC & SDGR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | FSBC | SDGR |
|---|---|---|
| Founded | 2002 | 1990 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 860.4M | 925.8M |
| IPO Year | 2021 | 2020 |
| Metric | FSBC | SDGR |
|---|---|---|
| Price | $40.99 | $12.15 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 5 | 9 |
| Target Price | ★ $41.90 | $21.00 |
| AVG Volume (30 Days) | 76.1K | ★ 1.3M |
| Earning Date | 04-27-2026 | 05-05-2026 |
| Dividend Yield | ★ 2.47% | N/A |
| EPS Growth | 28.32 | ★ 45.14 |
| EPS | ★ 0.87 | N/A |
| Revenue | N/A | ★ $255,869,000.00 |
| Revenue This Year | $30.25 | $0.76 |
| Revenue Next Year | $12.30 | $4.60 |
| P/E Ratio | $47.31 | ★ N/A |
| Revenue Growth | N/A | ★ 23.29 |
| 52 Week Low | $26.26 | $10.95 |
| 52 Week High | $42.26 | $27.63 |
| Indicator | FSBC | SDGR |
|---|---|---|
| Relative Strength Index (RSI) | 55.03 | 47.21 |
| Support Level | $39.92 | $11.18 |
| Resistance Level | $41.58 | $13.36 |
| Average True Range (ATR) | 1.00 | 0.65 |
| MACD | -0.11 | -0.06 |
| Stochastic Oscillator | 51.81 | 32.53 |
Five Star Bancorp is a bank holding company that operates in California through its subsidiary, a state-chartered non-member bank. The company provides a broad range of banking products and services to small and medium-sized businesses, professionals, and individuals. It offers loan products like commercial real estate loans, commercial loans, commercial land and construction loans, and farmland loans, and offers deposit products like checking accounts, savings accounts, money market accounts, and term certificate accounts. The group has one reportable operating segment: Banking.
Schrodinger Inc is a healthcare-based software company. It offers software solutions designed to support and accelerate the discovery, design, and optimization of molecules. The company operates in two reportable segments: Software and Drug Discovery. The software segment is focused on selling software to transform drug discovery across the life sciences industry, as well as to customers in materials science industries. The drug discovery segment is focused on generating revenue from a diverse portfolio of preclinical and clinical programs, internally and through collaborations, that have various stages of discovery and development. The majority of the company's revenue is derived from the Software segment. Geographically, it derives the maximum revenue from the United States.